In one study, treatment of mice with recombinant mouse OPG protein inhibited prostate tumor-induced osteoclastogenesis and tumor growth in bone but had no effect on subcutaneous tumor growth, suggesting the absence of a direct antitumor effect (13). The gene discussed is TNFRSF11B; the disease is neoplasm.